Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2021 Oct 20;89(1):49–58. doi: 10.1007/s00280-021-04350-x

FIG 1.

FIG 1.

Veliparib dose proportionality in Groups 1 and 2. (A) Mean (+SD) veliparib Cmax vs veliparib dose. (B) Mean AUC0-7 vs veliparib dose Cycle 1 Day 1. (C) Dose-normalized Cmax Cycle 1 Day 1 vs dose-normalized observed Cmax Cycle 1 Day 3 and Cycle 2 Day 1. (D) Dose normalized AUC0-∞ Cycle 1 Day 1 vs dose-normalized AUC0-12 Cycle 1 Day 3 and dose-normalized AUC Cycle 2 Day 1.